The ARFIP2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited human lung epithelial cell population with targeted disruption of the ARFIP2 gene. This polyclonal knockout model consists of a heterogeneous pool of A-549 cells harboring diverse loss-of-function mutations, providing a robust system to study ARFIP2 deficiency without clonal selection bias. It enables systematic interrogation of ARFIP2-dependent pathways in a physiologically relevant adenocarcinoma background, suitable for mechanistic and screening studies.
The A-549 cell line is a widely used model of human non-small cell lung adenocarcinoma, originally isolated from a 58-year-old Caucasian male. These epithelial cells retain active EGFR and PI3K signaling and are extensively utilized to investigate lung cancer cell migration, invasion, and metastatic dissemination. The polyclonal knockout format preserves the intrinsic heterogeneity of the parental line while introducing ARFIP2 loss, enabling studies that reflect tumor cell population variability.
ARFIP2 encodes a scaffold protein that directly interacts with ARF GTPases (ARF1/5/6) and Rac1, serving as a critical node coupling ARF6-mediated membrane trafficking to Rac1-driven actin polymerization. Activated downstream of integrin and EGFR signaling, it integrates PI3K inputs to promote ARF6-GTP and Rac1-GTP coupling at the plasma membrane, stimulating effectors PAK and WAVE2 and the ARP2/3 complex to drive branched actin assembly. ARFIP2 also coordinates focal adhesion dynamics by modulating paxillin localization and E-cadherin trafficking, facilitating lamellipodia formation and membrane ruffling during cell migration.
In A-549 adenocarcinoma cells, ARFIP2 knockout disrupts migratory and invasive processes, offering a powerful tool for dissecting cancer metastasis mechanisms. Loss of ARFIP2 attenuates ARF6-Rac1 crosstalk, impairing actin-driven membrane protrusion and focal adhesion maturation essential for cell motility. Additionally, these cells provide a platform to explore the intersection of metabolic signaling and tumor behavior, given ARFIP2??s role in insulin secretion, and enable assessment of type 2 diabetes-related regulatory pathways.
Researchers can utilize these cells in transwell migration and invasion assays, wound healing scratch assays, and immunofluorescence staining for actin and paxillin to assess motility and adhesion dynamics. Co-immunoprecipitation and GTPase pull-down assays characterize ARFIP2 interactomes and Rac1/ARF6 activities, while phospho-signaling and RNA-seq analyses reveal downstream transcriptional responses. The polyclonal population is also amenable to anti-metastatic drug screening targeting ARF-Rac1 crosstalk. For technical inquiries, contact Ascent Research.
